meningioma contraindacation to peptides meningiomas - PRRTmeningioma side effects Meningioma Contraindications to Peptides: A Comprehensive Overview

EANM guidelines Meningiomas, the most common primary brain tumors in adults, are typically benign intracranial neoplasms that arise from the meninges. While often curable with surgical resection and radiotherapy (RT), treatment for recurrent, progressive, or aggressive meningiomas can be challenging. In recent years, Peptide Receptor Radionuclide Therapy (PRRT) has emerged as a promising investigational treatment, particularly for advanced or refractory cases.Peptide Receptor Radionuclide Therapy in Advanced ... However, like any medical intervention, PRRT has its own set of contraindications and potential side effects. Understanding these is crucial for safe and effective patient management.

Understanding Peptide Receptor Radionuclide Therapy (PRRT) in Meningiomas

PRRT is a form of targeted therapy that delivers high doses of radiation directly to tumor cells.2020年9月3日—A recent cohort study in France has demonstrated a dose-dependent association between cyproterone acetate and the risk ofmeningioma. This approach leverages the expression of somatostatin receptors (SSTRs) on many meningiomas, similar to their presence on neuroendocrine tumors. Peptides such as octreotate, when radiolabeled, can bind to these receptors, allowing for the targeted delivery of therapeutic radionuclides like Lutetium-177 (¹⁷⁷Lu) or Iodine-111 (¹¹¹In). Studies, including retrospective analyses, have indicated that PRRT with agents like ¹¹¹In-Pentetreotide can be safe, well-tolerated, and effective in controlling disease in patients with meningiomas. The theranostic use of radiolabeled dota-peptides also allows for simultaneous diagnostic imaging and targeted therapy.

Contraindications for PRRT in Meningiomas

While PRRT offers a valuable treatment option, certain conditions can preclude its use.(PDF) Joint EANM/EANO/RANO/SNMMI practice guideline ... The contraindications for PRRT in meningioma are largely adapted from guidelines for its use in neuroendocrine tumors.作者：NL Albert·2024·被引用次数：44—Contraindications. Contraindications for PRRT in meningioma are adapted from the guideline for PRRT in neuroendocrine tumours [17]. Absolute: ... These can be broadly categorized as absolute and relative.

Absolute Contraindications:

* Severe Renal Impairment: Patients with significantly compromised kidney function may not be able to adequately excrete the radiolabeled peptides, leading to prolonged radiation exposure and potential toxicity to healthy organs.

* Severe Bone Marrow Suppression: Pre-existing conditions leading to severe suppression of bone marrow function can be exacerbated by the myelosuppressive effects of PRRT, increasing the risk of infections and bleedingIn Nuclear Medicine,PeptideReceptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE, currently used on a compassionate basis in refractorymeningioma, deploys ....

* Active Infection: PRRT should generally not be administered to patients with active, uncontrolled infections due to the increased risk of complications.

Relative Contraindications and Precautions:

* Pregnancy and Breastfeeding: Due to the radioactive nature of the treatment, PRRT is contraindicated in pregnant and breastfeeding individuals to protect the developing fetus or infant.

* Certain Familial Syndromes: While not an absolute contraindication, certain familial syndromes that predispose individuals to meningioma development might warrant careful consideration and risk-benefit assessment.

* Prior High-Dose Radiation Exposure: Patients who have received extensive prior radiation therapy, particularly to the same or nearby areas, may have limited tolerance for additional radiationEstrogen Hormone Replacement Therapy in Incidental Meningioma.

* Specific Drug Therapies: The use of certain medications can influence the efficacy or safety of PRRT. For instance, long-term use of some progestogen drugs has been linked to an increased risk of meningioma, and their concurrent use with PRRT would require careful evaluationInnovative treatments for meningiomas. Similarly, while chemotherapy and targeted therapies are used for meningiomas, their efficacy can be limited, and they may present side effects.Meningiomasare the most the common primary brain tumors in adults, representing approximately a third of all intracranial neoplasms. The interplay between these treatments and PRRT needs thorough consideration.

Potential Side Effects of PRRT

While PRRT is generally considered safe and well-tolerated, potential side effects can occur. These are often related to the radiation dose delivered and the peptides usedEarly Preventive Strategies and CNS Meningioma. Common side effects can include:

* Gastrointestinal Disturbances: Nausea, vomiting, diarrhea, and abdominal pain are frequently reported.

* Hematological Toxicity: Bone marrow suppression leading to decreased white blood cell counts (leukopenia), red blood cell counts (anemia), and platelet counts (thrombocytopenia) can occur作者：JZ Wang·2024·被引用次数：100—... risk ofmeningiomadevelopment, relatively few modifiable risk factors have been definitively identified. These few include ionizingradiation.... Regular blood monitoring is essential.

* Renal Toxicity: Mild to moderate kidney dysfunction can manifest, necessitating careful monitoring of renal function.

* Hepatic Toxicity: Liver function may be affected in some patients.

* Fatigue: A general feeling of tiredness is a common complaintResearch has shown that Depo-Provera use may be tied to a type of tumor called ameningioma. Learn more about the risks and lawsuits..

It is important to note that the incidence and severity of these side effects can vary depending on the specific radiopharmaceutical used, the administered dose, the patient's overall health status, and the presence of other concurrent medical conditions.

Other Considerations in Meningioma Treatment

Beyond PRRT, other treatment modalities for meningiomas exist, each with its own considerations. Surgery remains the primary treatment for many meningiomas2024年6月20日—Moreover, SSTR-peptidereceptor radionuclide therapy (PRRT) is an emerging investigational treatment approach formeningioma. Conclusion These .... Radiotherapy, including external beam radiotherapy (EBRT), is often used for irresectable tumors or as adjuvant therapy.Prescribing and Medicines Optimisation Guidance (13) Systemic medical therapies, including chemotherapy and targeted therapies like Anti-VEGF and mTOR inhibitors, are typically reserved for treatment-refractory meningiomas or used within clinical trials.

Furthermore, certain medications have been associated with an increased risk of meningioma development. For example, high doses of cyproterone acetate and medroxyprogesterone acetate have demonstrated a dose-dependent association with meningioma risk. Research has also indicated a potential link between Depo-Provera use and meningiomaInnovative treatments for meningiomas. Awareness of these associations is important for both risk assessment and management.

In conclusion, while Peptide Receptor Radionuclide Therapy represents an evolving and promising avenue for managing complex meningiomas, a thorough understanding of its contraindications and potential side effects is paramount. This includes considering the patient's overall health, existing medical conditions, and concurrent medications to ensure the safest and most effective treatment strategy.Theragnostic Use of Radiolabelled Dota-Peptides in ... The EANM guidelines provide a framework for such considerations, emphasizing the need for individualized treatment planning.